(0.11%) 5 186.21 points
(0.07%) 38 879 points
(-0.09%) 16 335 points
(0.25%) $78.68
(0.68%) $2.21
(-0.36%) $2 322.80
(-0.43%) $27.50
(2.44%) $988.45
(0.18%) $0.930
(0.86%) $10.92
(0.45%) $0.800
(-0.07%) $91.28
-3.39% $ 3.00
@ $3.74
Wydano: 14 vas. 2024 @ 19:33
Zwrot: -19.92%
Poprzedni sygnał: vas. 14 - 18:06
Poprzedni sygnał:
Zwrot: 0.00 %
Live Chart Being Loaded With Signals
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally...
Stats | |
---|---|
Dzisiejszy wolumen | 383 314 |
Średni wolumen | 1.19M |
Kapitalizacja rynkowa | 447.62M |
EPS | $0 ( 2024-03-26 ) |
Następna data zysków | ( $0 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.97 |
ATR14 | $0.00400 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-08 | Ekblom Anders | Buy | 45 000 | Share Options (Right to buy) |
2024-02-08 | Ekblom Anders | Buy | 19 471 | Deferred Restricted Stock Units |
2024-02-08 | Jacquet Pierre | Buy | 45 000 | Share Options (Right to buy) |
2024-02-08 | Jacquet Pierre | Buy | 15 553 | Deferred Restricted Stock Units |
2024-02-08 | Yoskowitz Marc J | Buy | 45 000 | Share Options (Right to buy) |
INSIDER POWER |
---|
-60.62 |
Last 97 transactions |
Buy: 2 158 393 | Sell: 9 188 547 |
Wolumen Korelacja
Mereo BioPharma Group plc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
CFBK | 0.888 |
SLNO | 0.887 |
PBPB | 0.885 |
PROV | 0.873 |
ECOR | 0.867 |
ARDX | 0.865 |
RBKB | 0.861 |
ISTR | 0.854 |
CXDO | 0.854 |
CPLP | 0.851 |
10 Najbardziej negatywne korelacje | |
---|---|
OSMT | -0.878 |
PFBI | -0.858 |
HCM | -0.847 |
MLVF | -0.847 |
IQ | -0.844 |
RMRM | -0.843 |
BFRI | -0.838 |
COCO | -0.833 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Mereo BioPharma Group plc Korelacja - Waluta/Towar
Mereo BioPharma Group plc Finanse
Annual | 2023 |
Przychody: | $10.00M |
Zysk brutto: | $7.43M (74.26 %) |
EPS: | $0 |
FY | 2023 |
Przychody: | $10.00M |
Zysk brutto: | $7.43M (74.26 %) |
EPS: | $0 |
FY | 2022 |
Przychody: | $1.51M |
Zysk brutto: | $571 000 (37.89 %) |
EPS: | $-0.280 |
FY | 2021 |
Przychody: | $36.46M |
Zysk brutto: | $18.56M (50.89 %) |
EPS: | $0.159 |
Financial Reports:
No articles found.
Mereo BioPharma Group plc
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej